查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1566964

Atorvastatin钙市场：按形式、应用、分销管道分类：2024-2033 年全球机会分析和产业预测

Atorvastatin Calcium Market By Form , By Application By Distribution channel : Global Opportunity Analysis and Industry Forecast, 2024-2033
出版日期: | 出版商: Allied Market Research | 英文 280 Pages | 商品交期: 2-3个工作天内

价格
简介目录

2023年Atorvastatin钙市值为2.983亿美元，预计2024年至2033年复合年增长率为5%，2033年达到4.878亿美元。

Atorvastatin钙是一种他汀类药物，是预防心血管疾病的第一线药物。它透过抑制 HMG-CoA 还原酶来降低血液胆固醇水平，HMG-CoA 还原酶在肝臟胆固醇合成中起着重要作用。该药物可有效降低低密度脂蛋白（LDL）胆固醇，也可能有助于提高高密度脂蛋白（HDL）胆固醇。透过控制胆固醇水平，Atorvastatin钙在预防心臟病、中风和其他严重心血管事件方面发挥重要作用。

全球Atorvastatin钙市场的成长主要是由心血管疾病盛行率的惊人成长所推动的。根据世界心臟联盟的数据，心血管疾病是全球第一大死因，超过其他原因。 2021 年，全球报告死亡人数约 2,050 万人。此外，老年人口的快速增加也对市场成长做出了重大贡献。这是由于老年人更容易患高胆固醇症和相关心血管疾病，导致对Atorvastatin等降胆固醇药物的需求增加，从而推动市场成长。根据美国心臟协会2019年心臟病和中风统计更新，60至79岁族群心血管疾病的发生率据通报男性为77.2%，女性为78.2%。此外，久坐的生活方式和不健康的饮食模式导致人群胆固醇水平升高，从而增加了对Atorvastatin钙的需求。此外，大众对控制胆固醇水平对整体健康重要性的认识不断提高，以及Atorvastatin学名药仿製药的可用性正在推动全球市场的成长。联合治疗的日益普及是预计促进市场成长的主要趋势。例如，Atorvastatin钙和其他药物（例如ezetimibe）的组合越来越普遍，以增强胆固醇管理的治疗效果。然而，人们越来越担心Atorvastatin钙的潜在副作用，例如肌肉疼痛、肝损伤以及与其他药物的相互作用，可能会限制其使用并阻碍市场成长。此外，替代他汀类药物和其他降胆固醇药物的供应也是全球市场的主要阻碍因素。相反，配方和给药系统的创新正在提高Atorvastatin钙的功效和便利性，预计将为预测期内的市场成长提供有利的机会。

全球Atorvastatin钙市场按形式、应用、分销管道和地区细分。按形式划分，市场分为锭剂和其他类型。依用途分为高胆固醇症、高血脂症等。依分销通路划分，可分为医院药局、药局/零售药局、网路药局。从区域来看，分析包括北美、欧洲、亚太地区和拉丁美洲/中东/非洲。

主要发现

按格式划分，锭剂预计将在 2023 年锭剂2024 年至 2033 年占据市场主导地位。

透过应用，高胆固醇症预计将成为未来几年全球Atorvastatin钙市场中利润丰厚的部分。

从分销管道来看，预计到 2033 年，线上药局将成为主导细分市场。

按地区划分，就 2023 年收益而言，北美占据最大的市场占有率，预计将在预测期内主导Atorvastatin钙市场。

可以使用此报告进行客製化（需要额外费用和时间表）

  • 国家、区域和全球各级的患者/流行病学资料
  • 根据客户兴趣加入公司简介
  • 扩大公司简介列表
  • 历史市场资料
  • SWOT分析

目录

第一章简介

第 2 章执行摘要

第三章 市场状况

  • 市场定义和范围
  • 主要发现
    • 关键投资机会
    • 关键成功策略
  • 波特五力分析
  • 市场动态
    • 促进因素
    • 抑制因素
    • 机会

第四章Atorvastatin钙市场：依形式

  • 市场概况
  • 锭剂
  • 其他的

第五章 Atlastin 钙市：依应用分类

  • 市场概况
  • 高胆固醇症
  • 高血脂症
  • 其他的

第六章 阿曲他汀钙市场：依通路分类

  • 市场概况
  • 医院药房
  • 药局
  • 线上提供者

第七章阿曲他汀钙市场：依地区

  • 市场概况
  • 北美洲
    • 主要市场趋势和机会
    • 美国Atorvastatin钙市场
    • 加拿大Atorvastatin钙市场
    • 墨西哥Atorvastatin钙市场
  • 欧洲
    • 主要市场趋势和机会
    • 法国Atorvastatin钙市场
    • 德国Atorvastatin钙市场
    • 义大利Atorvastatin钙市场
    • 西班牙Atorvastatin钙市场
    • 英国Atorvastatin钙市场
    • 其他欧洲Atorvastatin钙市场
  • 亚太地区
    • 主要市场趋势和机会
    • 中国Atorvastatin钙市场
    • 日本Atorvastatin钙市场
    • 印度Atorvastatin钙市场
    • 韩国Atorvastatin钙市场
    • 澳洲Atorvastatin钙市场
    • 其他亚太地区Atorvastatin钙市场
  • 拉丁美洲/中东/非洲
    • 主要市场趋势和机会
    • 巴西阿托Atorvastatin钙市场
    • 南非Atorvastatin钙市场
    • 沙乌地Atorvastatin钙市场
    • 其他拉丁美洲/中东/非洲Atorvastatin钙市场

第八章 竞争格局

  • 介绍
  • 关键成功策略
  • 10家主要企业产品图谱
  • 竞争对手仪表板
  • 竞争热图
  • 主要企业定位（2023年）

第九章 公司简介

  • Mylan Pharmaceuticals Inc.
  • Novartis AG
  • GlaxoSmithKline Plc
  • Amgen Inc.
  • Sanofi SA
  • Teva Pharmaceuticals Industries Ltd
  • Merck And Co. Inc.
  • Bristol-Myers Squibb Company
  • AstraZeneca Plc
  • Pfizer Inc.
简介目录
Product Code: A324370

The atorvastatin calcium market was valued at $298.3 million in 2023, and is projected to reach $487.8 million by 2033, growing at a CAGR of 5% from 2024 to 2033.

Atorvastatin calcium is a statin medication, which acts as the first line of treatment for the prevention of cardiovascular diseases. It lowers the cholesterol levels in the blood by inhibiting the enzyme HMG-CoA reductase, which plays a crucial role in cholesterol synthesis in the liver. This medication is effective in lowering low-density lipoprotein (LDL) cholesterol, and can also help to raise high-density lipoprotein (HDL) cholesterol. By managing cholesterol levels, atorvastatin calcium plays a crucial role in preventing heart attacks, strokes, and other serious cardiovascular events.

The growth of the global atorvastatin calcium market is majorly driven by alarming increase in prevalence of cardiovascular diseases. According to the World Heart Federation, cardiovascular diseases are the leading cause of death worldwide as compared to any other cause. Approximately 20.5 million deaths were reported in 2021 across the globe. In addition, surge in geriatric population significantly contributes toward the market growth. This is attributed to the fact that aged individuals are highly susceptible to hypercholesterolemia and related cardiovascular conditions, which, in turn, leads to higher demand for cholesterol-lowering medications like atorvastatin, thereby boosting the market growth. As per AHA 2019 Heart Disease and Stroke Statistical Update, the incidence of cardiovascular diseases was reported to be 77.2% in males and 78.2% in females, from ages 60-79 years. Moreover, rise in sedentary lifestyles and unhealthy eating patterns are leading to higher cholesterol levels among the population, thereby increasing the need for atorvastatin calcium. Furthermore, rise in public awareness of the importance of managing cholesterol levels for overall health and availability of generic versions of atorvastatin calcium boost the growth of the global market. Increase in popularity of combination therapies acts a key trend that is expected to augment the market growth. For instance, the use of atorvastatin calcium in combination with other drugs, such as ezetimibe, is becoming more common to enhance therapeutic outcomes for managing cholesterol levels. However, rise in concerns about potential side effects of atorvastatin calcium such as muscle pain, liver damage, and interactions with other medications can limit its use, which hampers the market growth. In addition, availability of alternative statins and other cholesterol-lowering drugs acts as key deterrent factor of the global market. On the contrary, innovations in drug formulation and delivery systems are enhancing the efficacy and convenience of atorvastatin calcium, which are expected to offer lucrative opportunities for the market growth during the forecast period.

The global atorvastatin calcium market is segmented into form, application, distribution channel, and region. On the basis of form, the market is categorized into tablets and others. By application, it is divided into hypercholesterolemia, hyperlipidemia, and others. Depending on distribution channel, it is categorized into hospital pharmacies, drug store & retail pharmacies, and online providers. Region wise, the market is analyzed across North America, Europe, Asia-Pacific, and LAMEA.

Key Findings

On the basis of form, the tablets segment dominated the market in 2023, and is is expected to dominate from 2024 to 2033.

By application, hypercholesterolemia is anticipated to be the lucrative segment in the global atorvastatin calcium market in the coming years.

Depending on distribution channel, online pharmacies is projected to emerge as the leading segment by 2033.

Region wise, North America held the largest market share in terms of revenue in 2023, and is expected to dominate the atorvastatin calcium market during the forecast period.

Competition Analysis

Competitive analysis and profiles of the major players in the global atorvastatin calcium market include Mylan Pharmaceuticals Inc., Novartis AG, GlaxoSmithKline plc, Amgen Inc., Sanofi SA, Teva Pharmaceuticals Industries Ltd, Merck and Co. Inc., Bristol-Myers Squibb Company, AstraZeneca Plc., and Pfizer Inc. These major players have adopted various key development strategies such as business expansion, new product launches, and partnerships to sustain the intense competition and gain a strong foothold in the global market.

Additional benefits you will get with this purchase are:

  • Quarterly Update and* (only available with a corporate license, on listed price)
  • 5 additional Company Profile of client Choice pre- or Post-purchase, as a free update.
  • Free Upcoming Version on the Purchase of Five and Enterprise User License.
  • 16 analyst hours of support* (post-purchase, if you find additional data requirements upon review of the report, you may receive support amounting to 16 analyst hours to solve questions, and post-sale queries)
  • 15% Free Customization* (in case the scope or segment of the report does not match your requirements, 15% is equivalent to 3 working days of free work, applicable once)
  • Free data Pack on the Five and Enterprise User License. (Excel version of the report)
  • Free Updated report if the report is 6-12 months old or older.
  • 24-hour priority response*
  • Free Industry updates and white papers.

Possible Customization with this report (with additional cost and timeline, please talk to the sales executive to know more)

  • Patient/epidemiology data at country, region, global level
  • Additional company profiles with specific to client's interest
  • Expanded list for Company Profiles
  • Historic market data
  • SWOT Analysis

Key Market Segments

By Form

  • Tablets
  • Others

By Application

  • Hypercholesterolemia
  • Hyperlipidemia
  • Others

By Distribution Channel

  • Hospital pharmacies
  • Drug store retail pharmacies
  • Online providers.

By Region

  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • France
    • Germany
    • Italy
    • Spain
    • UK
    • Rest of Europe
  • Asia-Pacific
    • China
    • Japan
    • India
    • South Korea
    • Australia
    • Rest of Asia-Pacific
  • LAMEA
    • Brazil
    • South Africa
    • Saudi Arabia
    • Rest of LAMEA

Key Market Players:

    • Mylan Pharmaceuticals Inc.
    • Novartis AG
    • GlaxoSmithKline plc
    • Amgen Inc.
    • Sanofi SA
    • Teva Pharmaceuticals Industries Ltd
    • Merck and Co. Inc.
    • Bristol-Myers Squibb Company
    • AstraZeneca Plc
    • Pfizer Inc.

TABLE OF CONTENTS

CHAPTER 1: INTRODUCTION

  • 1.1. Report Description
  • 1.2. Key Market Segments
  • 1.3. Key Benefits
  • 1.4. Research Methodology
    • 1.4.1. Primary Research
    • 1.4.2. Secondary Research
    • 1.4.3. Analyst Tools and Models

CHAPTER 2: EXECUTIVE SUMMARY

  • 2.1. CXO Perspective

CHAPTER 3: MARKET LANDSCAPE

  • 3.1. Market Definition and Scope
  • 3.2. Key Findings
    • 3.2.1. Top Investment Pockets
    • 3.2.2. Top Winning Strategies
  • 3.3. Porter's Five Forces Analysis
    • 3.3.1. Bargaining Power of Suppliers
    • 3.3.2. Threat of New Entrants
    • 3.3.3. Threat of Substitutes
    • 3.3.4. Competitive Rivalry
    • 3.3.5. Bargaining Power among Buyers
  • 3.4. Market Dynamics
    • 3.4.1. Drivers
    • 3.4.2. Restraints
    • 3.4.3. Opportunities

CHAPTER 4: ATORVASTATIN CALCIUM MARKET, BY FORM

  • 4.1. Market Overview
    • 4.1.1 Market Size and Forecast, By Form
  • 4.2. Tablets
    • 4.2.1. Key Market Trends, Growth Factors and Opportunities
    • 4.2.2. Market Size and Forecast, By Region
    • 4.2.3. Market Share Analysis, By Country
  • 4.3. Others
    • 4.3.1. Key Market Trends, Growth Factors and Opportunities
    • 4.3.2. Market Size and Forecast, By Region
    • 4.3.3. Market Share Analysis, By Country

CHAPTER 5: ATORVASTATIN CALCIUM MARKET, BY APPLICATION

  • 5.1. Market Overview
    • 5.1.1 Market Size and Forecast, By Application
  • 5.2. Hypercholesterolemia
    • 5.2.1. Key Market Trends, Growth Factors and Opportunities
    • 5.2.2. Market Size and Forecast, By Region
    • 5.2.3. Market Share Analysis, By Country
  • 5.3. Hyperlipidemia
    • 5.3.1. Key Market Trends, Growth Factors and Opportunities
    • 5.3.2. Market Size and Forecast, By Region
    • 5.3.3. Market Share Analysis, By Country
  • 5.4. Others
    • 5.4.1. Key Market Trends, Growth Factors and Opportunities
    • 5.4.2. Market Size and Forecast, By Region
    • 5.4.3. Market Share Analysis, By Country

CHAPTER 6: ATORVASTATIN CALCIUM MARKET, BY DISTRIBUTION CHANNEL

  • 6.1. Market Overview
    • 6.1.1 Market Size and Forecast, By Distribution Channel
  • 6.2. Hospital Pharmacies
    • 6.2.1. Key Market Trends, Growth Factors and Opportunities
    • 6.2.2. Market Size and Forecast, By Region
    • 6.2.3. Market Share Analysis, By Country
  • 6.3. Drug Store Retail Pharmacies
    • 6.3.1. Key Market Trends, Growth Factors and Opportunities
    • 6.3.2. Market Size and Forecast, By Region
    • 6.3.3. Market Share Analysis, By Country
  • 6.4. Online Providers.
    • 6.4.1. Key Market Trends, Growth Factors and Opportunities
    • 6.4.2. Market Size and Forecast, By Region
    • 6.4.3. Market Share Analysis, By Country

CHAPTER 7: ATORVASTATIN CALCIUM MARKET, BY REGION

  • 7.1. Market Overview
    • 7.1.1 Market Size and Forecast, By Region
  • 7.2. North America
    • 7.2.1. Key Market Trends and Opportunities
    • 7.2.2. Market Size and Forecast, By Form
    • 7.2.3. Market Size and Forecast, By Application
    • 7.2.4. Market Size and Forecast, By Distribution Channel
    • 7.2.5. Market Size and Forecast, By Country
    • 7.2.6. U.S. Atorvastatin Calcium Market
      • 7.2.6.1. Market Size and Forecast, By Form
      • 7.2.6.2. Market Size and Forecast, By Application
      • 7.2.6.3. Market Size and Forecast, By Distribution Channel
    • 7.2.7. Canada Atorvastatin Calcium Market
      • 7.2.7.1. Market Size and Forecast, By Form
      • 7.2.7.2. Market Size and Forecast, By Application
      • 7.2.7.3. Market Size and Forecast, By Distribution Channel
    • 7.2.8. Mexico Atorvastatin Calcium Market
      • 7.2.8.1. Market Size and Forecast, By Form
      • 7.2.8.2. Market Size and Forecast, By Application
      • 7.2.8.3. Market Size and Forecast, By Distribution Channel
  • 7.3. Europe
    • 7.3.1. Key Market Trends and Opportunities
    • 7.3.2. Market Size and Forecast, By Form
    • 7.3.3. Market Size and Forecast, By Application
    • 7.3.4. Market Size and Forecast, By Distribution Channel
    • 7.3.5. Market Size and Forecast, By Country
    • 7.3.6. France Atorvastatin Calcium Market
      • 7.3.6.1. Market Size and Forecast, By Form
      • 7.3.6.2. Market Size and Forecast, By Application
      • 7.3.6.3. Market Size and Forecast, By Distribution Channel
    • 7.3.7. Germany Atorvastatin Calcium Market
      • 7.3.7.1. Market Size and Forecast, By Form
      • 7.3.7.2. Market Size and Forecast, By Application
      • 7.3.7.3. Market Size and Forecast, By Distribution Channel
    • 7.3.8. Italy Atorvastatin Calcium Market
      • 7.3.8.1. Market Size and Forecast, By Form
      • 7.3.8.2. Market Size and Forecast, By Application
      • 7.3.8.3. Market Size and Forecast, By Distribution Channel
    • 7.3.9. Spain Atorvastatin Calcium Market
      • 7.3.9.1. Market Size and Forecast, By Form
      • 7.3.9.2. Market Size and Forecast, By Application
      • 7.3.9.3. Market Size and Forecast, By Distribution Channel
    • 7.3.10. UK Atorvastatin Calcium Market
      • 7.3.10.1. Market Size and Forecast, By Form
      • 7.3.10.2. Market Size and Forecast, By Application
      • 7.3.10.3. Market Size and Forecast, By Distribution Channel
    • 7.3.11. Rest of Europe Atorvastatin Calcium Market
      • 7.3.11.1. Market Size and Forecast, By Form
      • 7.3.11.2. Market Size and Forecast, By Application
      • 7.3.11.3. Market Size and Forecast, By Distribution Channel
  • 7.4. Asia-Pacific
    • 7.4.1. Key Market Trends and Opportunities
    • 7.4.2. Market Size and Forecast, By Form
    • 7.4.3. Market Size and Forecast, By Application
    • 7.4.4. Market Size and Forecast, By Distribution Channel
    • 7.4.5. Market Size and Forecast, By Country
    • 7.4.6. China Atorvastatin Calcium Market
      • 7.4.6.1. Market Size and Forecast, By Form
      • 7.4.6.2. Market Size and Forecast, By Application
      • 7.4.6.3. Market Size and Forecast, By Distribution Channel
    • 7.4.7. Japan Atorvastatin Calcium Market
      • 7.4.7.1. Market Size and Forecast, By Form
      • 7.4.7.2. Market Size and Forecast, By Application
      • 7.4.7.3. Market Size and Forecast, By Distribution Channel
    • 7.4.8. India Atorvastatin Calcium Market
      • 7.4.8.1. Market Size and Forecast, By Form
      • 7.4.8.2. Market Size and Forecast, By Application
      • 7.4.8.3. Market Size and Forecast, By Distribution Channel
    • 7.4.9. South Korea Atorvastatin Calcium Market
      • 7.4.9.1. Market Size and Forecast, By Form
      • 7.4.9.2. Market Size and Forecast, By Application
      • 7.4.9.3. Market Size and Forecast, By Distribution Channel
    • 7.4.10. Australia Atorvastatin Calcium Market
      • 7.4.10.1. Market Size and Forecast, By Form
      • 7.4.10.2. Market Size and Forecast, By Application
      • 7.4.10.3. Market Size and Forecast, By Distribution Channel
    • 7.4.11. Rest of Asia-Pacific Atorvastatin Calcium Market
      • 7.4.11.1. Market Size and Forecast, By Form
      • 7.4.11.2. Market Size and Forecast, By Application
      • 7.4.11.3. Market Size and Forecast, By Distribution Channel
  • 7.5. LAMEA
    • 7.5.1. Key Market Trends and Opportunities
    • 7.5.2. Market Size and Forecast, By Form
    • 7.5.3. Market Size and Forecast, By Application
    • 7.5.4. Market Size and Forecast, By Distribution Channel
    • 7.5.5. Market Size and Forecast, By Country
    • 7.5.6. Brazil Atorvastatin Calcium Market
      • 7.5.6.1. Market Size and Forecast, By Form
      • 7.5.6.2. Market Size and Forecast, By Application
      • 7.5.6.3. Market Size and Forecast, By Distribution Channel
    • 7.5.7. South Africa Atorvastatin Calcium Market
      • 7.5.7.1. Market Size and Forecast, By Form
      • 7.5.7.2. Market Size and Forecast, By Application
      • 7.5.7.3. Market Size and Forecast, By Distribution Channel
    • 7.5.8. Saudi Arabia Atorvastatin Calcium Market
      • 7.5.8.1. Market Size and Forecast, By Form
      • 7.5.8.2. Market Size and Forecast, By Application
      • 7.5.8.3. Market Size and Forecast, By Distribution Channel
    • 7.5.9. Rest of LAMEA Atorvastatin Calcium Market
      • 7.5.9.1. Market Size and Forecast, By Form
      • 7.5.9.2. Market Size and Forecast, By Application
      • 7.5.9.3. Market Size and Forecast, By Distribution Channel

CHAPTER 8: COMPETITIVE LANDSCAPE

  • 8.1. Introduction
  • 8.2. Top Winning Strategies
  • 8.3. Product Mapping of Top 10 Player
  • 8.4. Competitive Dashboard
  • 8.5. Competitive Heatmap
  • 8.6. Top Player Positioning, 2023

CHAPTER 9: COMPANY PROFILES

  • 9.1. Mylan Pharmaceuticals Inc.
    • 9.1.1. Company Overview
    • 9.1.2. Key Executives
    • 9.1.3. Company Snapshot
    • 9.1.4. Operating Business Segments
    • 9.1.5. Product Portfolio
    • 9.1.6. Business Performance
    • 9.1.7. Key Strategic Moves and Developments
  • 9.2. Novartis AG
    • 9.2.1. Company Overview
    • 9.2.2. Key Executives
    • 9.2.3. Company Snapshot
    • 9.2.4. Operating Business Segments
    • 9.2.5. Product Portfolio
    • 9.2.6. Business Performance
    • 9.2.7. Key Strategic Moves and Developments
  • 9.3. GlaxoSmithKline Plc
    • 9.3.1. Company Overview
    • 9.3.2. Key Executives
    • 9.3.3. Company Snapshot
    • 9.3.4. Operating Business Segments
    • 9.3.5. Product Portfolio
    • 9.3.6. Business Performance
    • 9.3.7. Key Strategic Moves and Developments
  • 9.4. Amgen Inc.
    • 9.4.1. Company Overview
    • 9.4.2. Key Executives
    • 9.4.3. Company Snapshot
    • 9.4.4. Operating Business Segments
    • 9.4.5. Product Portfolio
    • 9.4.6. Business Performance
    • 9.4.7. Key Strategic Moves and Developments
  • 9.5. Sanofi SA
    • 9.5.1. Company Overview
    • 9.5.2. Key Executives
    • 9.5.3. Company Snapshot
    • 9.5.4. Operating Business Segments
    • 9.5.5. Product Portfolio
    • 9.5.6. Business Performance
    • 9.5.7. Key Strategic Moves and Developments
  • 9.6. Teva Pharmaceuticals Industries Ltd
    • 9.6.1. Company Overview
    • 9.6.2. Key Executives
    • 9.6.3. Company Snapshot
    • 9.6.4. Operating Business Segments
    • 9.6.5. Product Portfolio
    • 9.6.6. Business Performance
    • 9.6.7. Key Strategic Moves and Developments
  • 9.7. Merck And Co. Inc.
    • 9.7.1. Company Overview
    • 9.7.2. Key Executives
    • 9.7.3. Company Snapshot
    • 9.7.4. Operating Business Segments
    • 9.7.5. Product Portfolio
    • 9.7.6. Business Performance
    • 9.7.7. Key Strategic Moves and Developments
  • 9.8. Bristol-Myers Squibb Company
    • 9.8.1. Company Overview
    • 9.8.2. Key Executives
    • 9.8.3. Company Snapshot
    • 9.8.4. Operating Business Segments
    • 9.8.5. Product Portfolio
    • 9.8.6. Business Performance
    • 9.8.7. Key Strategic Moves and Developments
  • 9.9. AstraZeneca Plc
    • 9.9.1. Company Overview
    • 9.9.2. Key Executives
    • 9.9.3. Company Snapshot
    • 9.9.4. Operating Business Segments
    • 9.9.5. Product Portfolio
    • 9.9.6. Business Performance
    • 9.9.7. Key Strategic Moves and Developments
  • 9.10. Pfizer Inc.
    • 9.10.1. Company Overview
    • 9.10.2. Key Executives
    • 9.10.3. Company Snapshot
    • 9.10.4. Operating Business Segments
    • 9.10.5. Product Portfolio
    • 9.10.6. Business Performance
    • 9.10.7. Key Strategic Moves and Developments